Clinico-morphological changes in ectropion after treatment with polydeoxyribonucleotide (PDRN)

Thirty patients in fertile age affected by ectropion were treated with Polydeoxyribonucleotide (PDRN) (*) vaginal suppositories for 24 days. No other local or general therapy was allowed. The following parameters were evaluated: local symptomatology, tolerability and compliance, vaginal cytology, co...

Full description

Saved in:
Bibliographic Details
Published inAnnali di ostetricia, ginecologia, medicina perinatale Vol. 111; no. 6; p. 379
Main Authors De Luca Brunori, I, Urbano, M, Romani, L, Tarani, A, Felipetto, R, Battini, L, Amato, A, Andreoni, P
Format Journal Article
LanguageItalian
Published Italy 01.11.1990
Subjects
Adolescent
Adult
Cervix Uteri - cytology
Cervix Uteri - pathology
Colposcopy
Drug Tolerance
Female
Humans
Middle Aged
Polydeoxyribonucleotides - administration & dosage
Polydeoxyribonucleotides - therapeutic use
Suppositories
Uterine Cervical Diseases - diagnosis
Uterine Cervical Diseases - drug therapy
Uterine Cervical Diseases - pathology
Vaginal Smears
Online AccessGet more information

Cover

More Information
Summary:Thirty patients in fertile age affected by ectropion were treated with Polydeoxyribonucleotide (PDRN) (*) vaginal suppositories for 24 days. No other local or general therapy was allowed. The following parameters were evaluated: local symptomatology, tolerability and compliance, vaginal cytology, colposcopic examination, bioptic sampling of affected area prior to and after treatment, and local immune response. The results show the efficacy of PDRN. In fact, after the treatment: reduction of subjective symptomatology with decrease of average score for each symptom; excellent or good tolerability and acceptability; reduced inflammation; increased iodine-dark areas; reestablishment of normal balance in T- and B-lymphocytic populations have been found.
ISSN:0300-0087